PHI’s board members and advisors complete warrant redemption
Phase Holographic Imaging PHI AB ("PHI") has earlier announced that US citizens participating in the warrant program for board members and advisors have not been able to redeem their warrants due to administrative banking issues. These issues have now been resolved, which means that the company will additionally receive approximately 1.8 MSEK and that all warrants in the two programs will be redeemed. The remaining warrants now being redeemed are held by Leland Foster, board member, and the advisors Cynthia Collins and Ron Lowy, who all subscribed for the shares in the middle of 2017 before the final subscription day of the programs.
WARRANT PROGRAM
The warrant programs, for which the final subscription day was October 24, 2017, were established prior to the company’s listing on Spotlight Stock Market (earlier AktieTorget). With respective subscription prices of 16.50 SEK/share and 12.80 SEK/share, the remaining 21 532 and 110 000 shares in the two programs are now being issued. The issuing of these 131 532 shares will dilute current holdings with 0.97 %, given that the ongoing rights issue is fully subscribed.
For additional information regarding the rights issue see www.phiab.se/rights-issue.
For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: ir@phiab.se
Web: www.phiab.se
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.